Amgen Reports Second Quarter 2021 Financial Results
Amgen today announced financial results for the second quarter of 2021. Key results include: Total revenues increased 5% to $6.5 billion in comparison to the second quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® Repatha ® and our biosimilar …
– Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2021. Key results include: Total revenues increased 5% to $6.5 billion in comparison to the second quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices.
Think Research Brings Leading Oncology Education Conference to Australia and United Kingdom
News provided by
Share this article
Share this article
Expanded partnership with American Society of Clinical Oncology (ASCO) brings latest clinical oncology knowledge to new markets
TORONTO, April 7, 2021 /CNW/ - Think Research Corporation (TSXV: THNK) or (the Company or Think ), a company focused on transforming healthcare through integrated digital health software solutions, announced today it has secured licenses from the American Society of Clinical Oncology (ASCO) to host two new oncology education events in Australia and the United Kingdom, further positioning the company as a global leader in clinical education.
Home / Top News / Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
– Supplemental New Drug Application Planned for Submission in Q1 2021 –
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in .
Agios Pharmaceuticals, Inc.January 17, 2021 GMT
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib tablets) in patients with previously treated isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma. Data from the study were featured in an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), which is being held virtually January 15-17, 2021.